Information about Mitomycin
Mitomycin is a cytotoxic antibiotic which is used as anticancer therapy of advanced cancers of the stomach and pancreas.
Liver safety of Mitomycin
Mitomycin in combination with other anticancer agents frequently causes mild-to-moderate serum enzyme elevations during therapy and is capable of causing sinusoidal obstruction syndrome, but mitomycin by itself has not been specifically linked to instances of clinically apparent liver injury with jaundice.
Mechanism of action of Mitomycin
Mitomycin (mye” toe mye’ sin), which is also called mitomycin-C, is a cytotoxic antibiotic first isolated from Streptococcus caespitosus and later shown to have potent antitumor effects in vitro and in vivo.
Clinical use of Mitomycin
Mitomycin has clinical activity against several forms of malignancy, and combination therapies that include mitomycin have proven effective in several forms of solid tumors.
FDA approval information for Mitomycin
Mitomycin was approved for use in the United States in 2002 and current formal indications include advanced or disseminated stomach and pancreatic cancer.
Dosage and administration for Mitomycin
Because of its toxicities, however, mitomycin is now rarely used. Mitomycin is available as a solution or lyophilized powder for injection in vials of varying concentrations generically and under the commercial name Mutamycin. The typical dose of mitomycin varies by indication and is adjusted for body weight and renal function.
Side effects of Mitomycin
Side effects of mitomycin include bone marrow suppression, nausea, vomiting, diarrhea, stomatitis, rash, fever and malaise. Rare complications include hemolytic uremic syndrome, hemolysis, neurological abnormalities, renal failure and interstitial pneumonitis.